Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Building on the success of osimertinib: achieving CNS exposure in oncology drug discovery
Nicola Colclough, Kan Chen, Peter Johnström, et al.
Drug Discovery Today (2019) Vol. 24, Iss. 5, pp. 1067-1073
Closed Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs
Nicola Colclough, Kan Chen, Peter Johnström, et al.
Clinical Cancer Research (2020) Vol. 27, Iss. 1, pp. 189-201
Open Access | Times Cited: 169
Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and Development
Irena Loryan, Andreas Reichel, Bo Feng, et al.
Pharmaceutical Research (2022) Vol. 39, Iss. 7, pp. 1321-1341
Open Access | Times Cited: 70
Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood–Brain Barrier: The Discovery of AZD1390
Kurt G. Pike, Thomas A. Hunt, Bernard Barlaam, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 3090-3111
Closed Access | Times Cited: 7
Brain exposure of the ATM inhibitor AZD1390 in humans—a positron emission tomography study
Aurelija Jučaitė, Per Stenkrona, Zsolt Cselényi, et al.
Neuro-Oncology (2020) Vol. 23, Iss. 4, pp. 687-696
Open Access | Times Cited: 48
Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRASG12C with Demonstrable CNS Penetration
Jason G. Kettle, Sharan K. Bagal, Derek Barratt, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 13, pp. 9147-9160
Closed Access | Times Cited: 16
Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease
Anders W. Erickson, Priscilla K. Brastianos, Sunit Das
JAMA Network Open (2020) Vol. 3, Iss. 3, pp. e201617-e201617
Open Access | Times Cited: 38
The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discovery
Benoit Cox, Johan Nicolaï, Beth Williamson
Biopharmaceutics & Drug Disposition (2022) Vol. 44, Iss. 1, pp. 113-126
Closed Access | Times Cited: 20
Utilizing a Dual Human Transporter MDCKII-MDR1-BCRP Cell Line to Assess Efflux at the Blood Brain Barrier
Nicola Colclough, Ravindra V. Alluri, James W. Tucker, et al.
Drug Metabolism and Disposition (2023) Vol. 52, Iss. 2, pp. 95-105
Open Access | Times Cited: 11
Highly Optimized CNS Penetrant Inhibitors of EGFR Exon20 Insertion Mutations
William McCoull, Clare Thomson, Erin Braybrooke, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Assessing central nervous system drug delivery
Margareta Hammarlund‐Udenaes, Irena Loryan
Expert Opinion on Drug Delivery (2025)
Closed Access
Complete inhibition of ABCB1 and ABCG2 at the blood–brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib
Nicolas Tournier, Sébastien Goutal, Severin Mairinger, et al.
Journal of Cerebral Blood Flow & Metabolism (2020) Vol. 41, Iss. 7, pp. 1634-1646
Open Access | Times Cited: 23
A case of torsades de pointes induced by the third-generation EGFR-TKI, osimertinib combined with moxifloxacin
Shuang Bian, Xiaomiao Tang, Wei Lei
BMC Pulmonary Medicine (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 22
Assessing extent of brain penetration in vivo (Kp,uu,brain) in Göttingen minipig using a diverse set of reference drugs
Kristine Langthaler, Christopher R. Jones, Birger Brodin, et al.
European Journal of Pharmaceutical Sciences (2023) Vol. 190, pp. 106554-106554
Open Access | Times Cited: 7
Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood–Brain Barrier
Eurydice Angeli, Guilhem Bousquet
Pharmaceutics (2021) Vol. 13, Iss. 9, pp. 1446-1446
Open Access | Times Cited: 17
Progress of ATM inhibitors: opportunities and challenges
Shan Du, Qi Liang, Jianyou Shi
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116781-116781
Closed Access | Times Cited: 2
Optimization of Potent, Efficacious, Selective and Blood–Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations
Clare Thomson, Erin Braybrooke, Nicola Colclough, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
AKT/GSK3β/NFATc1 and ROS signal axes are involved in AZD1390-mediated inhibitory effects on osteoclast and OVX-induced osteoporosis
Shuyue Yang, Dezhi Song, Ziyi Wang, et al.
International Immunopharmacology (2022) Vol. 113, pp. 109370-109370
Closed Access | Times Cited: 9
Further Considerations Towards an Effective and Efficient Oncology Drug Discovery DMPK Strategy
Beth Williamson, Nicola Colclough, Adrian J. Fretland, et al.
Current Drug Metabolism (2020) Vol. 21, Iss. 2, pp. 145-162
Closed Access | Times Cited: 10
PEAMOtecan, a novel chronotherapeutic polymeric drug for brain cancer
Jasmine Allen, Juan Wang, O. Yu. Zolotarskaya, et al.
Journal of Controlled Release (2020) Vol. 321, pp. 36-48
Open Access | Times Cited: 9
Future Directions of AI In Pharma : Innovation In Pharmaceutical Industry
Priyanka B. Wanjul -, Sudarshan Parshuram Mourya -, Vaibhav Laxman Gangad -
International Journal For Multidisciplinary Research (2023) Vol. 5, Iss. 3
Open Access | Times Cited: 3
Blood retinal barrier and ocular pharmacokinetics: Considerations for the development of oncology drugs
Beth Williamson, Venkatesh Pilla Reddy
Biopharmaceutics & Drug Disposition (2021) Vol. 42, Iss. 4, pp. 128-136
Closed Access | Times Cited: 7
ADME Optimization in Drug Discovery
Dermot F. McGinnity, Ken Grime
The Royal Society of Chemistry eBooks (2023), pp. 298-323
Closed Access | Times Cited: 2
Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography
Beatrix Wulkersdorfer, Martin Bauer, Rudolf Karch, et al.
EJNMMI Research (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 4
Integration of Molecular Analysis, Cutting-edge Mouse Genetic Models and Proton Therapy to Improve Outcomes for Glioma Patients
Soma Sengupta, Luke Pater, Daniel Pomeranz Krummel, et al.
Exon Publications eBooks (2021), pp. 79-96
Open Access | Times Cited: 1
Data from Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs
Nicola Colclough, Kan Chen, Peter Johnström, et al.
(2023)
Open Access
Page 1 - Next Page

Scroll to top